Bacterial resistance is one of the main issues regarding public health worldwide, since most of the existing antibiotics are no longer effective against bacterial diseases. To that end, many microorganisms from different environments have been isolated and subjected under stress conditions to obtain secondary metabolites. Consequently, new bioactive compounds are isolated and chemically typified in order to be useful on the pharmaceutical industry.
Within the research, the antibiotic was produced using a bioreactor by injecting the bacterial strain identified as Bacillus megaterium (PAP48G3); obtaining in the production of 3 days an amount of 45.1 mg and in 4 days a total of 52.2 mg. Once the antibiotic was obtained, IR spectroscopy was performed which allowed to identify the main antibiotic functional groups, such as: Amino (N-H), Hydroxyl (O-H), Carbonyl (C = O), Alkane, and Alkoxy (ether). In addition, purification was carried out by thin layer chromatography, in which the best separation of molecules was obtained with the mobile phase composed of Ethyl Acetate-Chloroform (3:1); achieving then the separation of three bioactive compounds and through bioautography it was identified that the compound with Rf of 0.61 contains the antibiotic property against the selected pathogenic microorganisms. Finally, the minimum inhibitory concentration (MIC) was evaluated by performing microdilution in broth, obtaining an inhibition in 500 μg / mL for Pseudomona aeruginosa (ATCC 9027) and Bacillus spizizenii (ATCC 6633).